Locust Walk

Congratulations to the Xyphos Biosciences team for their acquisition by Astellas. They found a great partner to help them develop next generation cell therapies and we are very proud to have worked with such a great team. Click here to read the press release: http://bit.ly/XyphosAstellas

www.locustwalk.com

On Thursdays our Analysts match.

Lubor Gaal, SVP, Head of Europe at Locust Walk, sat down with EBD Group in preparation for his panel at .
http://bit.ly/LuborGaalPanel

www.locustwalk.com

Join Lubor Gaal of Locust Walk and his esteemed panelists at BIO-Europe November 12 from 10-11 am to discuss non-binding term sheets.

We want you to master one of the most important elements in a successful transaction process--the handling of the term sheet! Lubor Gaal's recent article in the September issue of BiopharmaDealmakers, "Biopharma Dealmaking: Negotiating Your Term Sheet," is available now. Click below to read (pages 13-14)
https://biopharmadealmakers.nature.com/pages/npg-latest-edition-bpdm

Latest edition | BioPharma Dealmakers

Locust Walk's medtech team has compiled key statistics and trends on strategic transactions and financings, with a focus on upcoming trends. Click below to download: http://bit.ly/Q3MedtechReport

Q3 2019 Report: Global Trends in Medtech Transactions - Locust Walk Q3 2019 Report: Global Trends in Medtech Transactions Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get t...

At the end of each quarter, our biopharma team here at Locust Walk reviews the global trends in biopharma transactions with an eye on future trends. Click below to download.
http://bit.ly/Q3BioReport

Based on recent acquisitions by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing validity. Download our whitepaper, Inside Out, written by Chris Ehrlich to join the discussion. http://bit.ly/insideoutwhitepaper

Whitepaper Download: Inside Out - Locust Walk Inside Out: Do Recent Acquisitions by “Big Pharma” Sound the Alarm for the Traditional R&D Model? Based on recent acquisition activity by two of the largest pharmaceutical companies, it seems as if the historical orthodoxy that great biopharma companies are made from the inside out may be losing...

Our CEO and Co-Founder, Geoff Meyerson, just returned from a month in Europe as part of our effort to expand Locust Walk European practice. It was a fantastic trip with valuable lessons. Click below to read.


http://bit.ly/EUVacation

What's the impact on partnerships for public biotech companies? Financing overhang or hangover? Click below to read more and join the discussion.

https://www.locustwalk.com/financing-overhang-or-hangover-the-impact-on-partnerships-for-public-biotech-companies/

Our medtech team took a deep dive into the Q2 data. Click below to download the report on latest trends and predictions for what's ahead.
http://bit.ly/Q2Medtech

As we close Q2, our global biopharma team has pulled the latest data with a keen eye on insights and trends. Click below to download!
http://bit.ly/Q2Biopharma

Locust Walk further expands financing team with appointments of Neil Higgins, Managing Director of Financing, and Turner Grant, Senior Vice President of Financing. Both executives will report to Brian W. Coleman, Global Head of Financing and Sales, as the firm continues to expand its capabilities to support capital raising for biopharma and medtech companies.

https://www.prnewswire.com/news-releases/locust-walk-further-expands-financing-team-with-appointments-of-neil-higgins-and-turner-grant-300871072.html

Geoff Meyerson, CEO of Locust Walk, will be joining his distinguished colleagues, industry CEOs, and board members at tomorrow's Board Meeting hosted by Crush Life Sciences to moderate the panel: Pricing Paradigm: A New Driver of Corporate Strategy. Joining him as panelists include Roger Longman, CEO of Real Endpoints, and Bruce Nash, Chief Physician Executive and Senior Vice President of Blue Cross Blue Shield of Massachusetts.

Geoff Meyerson to Moderate Panel at Crush Life Sciences Board Meeting - Locust Walk The Crush Life Sciences Board Meeting series is designed to open minds and explore new trends that will translate into more effective governance and success throughout the life science industry. The Board Meeting is an exclusive, invite-only, off the record meeting for life science CEOs and board me...

It's week and our team is getting ready for a productive and exciting week of meetings with biopharma companies! We are thrilled to be sponsoring such an important industry event. Philadelphia, here we come.

Locust Walk's Brian Coleman and Lubor Gaal will be attending Bio€quity Europe hosted by BioCentury. If you're a biopharma company faced with an expanding range of financing options and need assistance navigating your path, don't miss this panel!

Every day we're trufflin' ... actually, not really, just last night. Recapping a fun team building evening with those that could attend from our Boston office at the BCAE - Boston Center for Adult Education where we learned how to make hand-rolled chocolate truffles!

While Geoff Meyerson, CEO & Co-Founder of Locust Walk, was at the BIO CEO conference earlier this year, he sat down with
Global Business Reports to discuss the state of the biopharmaceutical industry. Click below to read: https://lnkd.in/dBnaAnb

www.locustwalk.com

"Clear, data-based financial assumptions are essential to driving a successful deal process," writes Nicholas DeLong, Associate at Locust Walk. Click here to read the full post: https://lnkd.in/drkZJZZ

Our team at Locust Walk hosted a networking event in Japan this week, bringing together women in business development from the pharma industry. Pictured here is Sara Fried, Director of Sales Operations, thanking all attendees for joining!

Biopharma indices climbed in Q1 2019 following a rocky end to 2018. Click here to download our full report on global trends in biopharma transactions: https://lnkd.in/dSacv_3

Q1 2019 is a wrap and our medtech team have the latest data, insights, and predictions for medtech. Click here to download the full report: https://lnkd.in/dxJsGFx

Looking to maximize the value of your company or asset? Geoff Meyerson, Chris Ehrlich, and Andrew Meyerson of Locust Walk put together a whitepaper addressing just that, "The Art of the Multi-Track Deal," sharing insight into how multiple deal options in parallel, known as the multi-track process, can create tension that will enable a company to obtain the most value out of the deal. Click here to read: https://lnkd.in/d3mddY3

2018 was a record year for venture capital financings into biotech, and a record number of institutional funds raised specifically for the life sciences. If you are looking to start fund raising this is a must read: https://buff.ly/2UJTS01

Trends in Venture Deal Term Sheets: Favorable Climate for Founders - Locust Walk Venture Deal Terms Sheets: What Do These Trends Mean? This article exposes the key issues facing life sciences entrepreneurs when it comes to negotiating a contract and key trends to look out for in the process.

2019 American Academy of Orthopedic Surgeons (AAOS) meeting was all about M&A and promising new technology including robotics, software, and digital surgery. Click here for more analysis from Hunt Henrie of Locust Walk!

Make No Bones About It – AAOS 2019 Was All About M&A and Promising New Technology - Locust Walk Related Posts Triangulation: The key to valuing early stage medical technology companies We’re All Heart: Best in Show at TCT Locust Walk expands Medical Technology Practice with the appointment of Hunt Henrie

"The sheer size of the domestic market and unmet medical needs in China combined with the maturing regulatory and commercial environment creates an unparalleled opportunity for homegrown innovation and in-licensed assets alike." Download our whitepaper, The Asia Factor, to learn more about how China and Japan are combining to invigorate the deal making landscape in Asia. http://bit.ly/TheAsiaFactorWhitepaper

If you're attending BIO-EUROPE SPRING, hosted by EBD Group this week, be sure to listen to the panel: The Art of the Multi-Track Deal: Keys to Maximizing the Value of Your Company on Monday at 2:45 pm, moderated by Lubor Gaal of Locust Walk, and panelists representing TVM Capital Life Science, Caribou Biosciences, Eli Lilly, and Targovax ASA

Hunt Henrie, Managing Director, Global Head of Medtech at Locust Walk is back from the AAOS conference and is making no bones about it – it was all about M&A and promising new technology.

Click here to read his post-AAOS commentary: http://bit.ly/AAOSBlogPost

Chris Ehrlich and Lubor Gaal are teaming up and representing Locust Walk at this year's conference, powered by the EBD Group. Looking to get a deal done in Europe? Contact us to see how we can partner with you on your next transformative transaction! https://www.locustwalk.com/contact-us/

Chris Ehrlich, Managing Director at Locust Walk and an alumni of The Rivers School, organized a trip for students from Boston's The Rivers School to tour San Francisco to explore high tech and biotech companies to gain inspiration as they look ahead to their future. On the last stop of their journey, Chris hosted them at his San Francisco office to talk biotech and Simon Walter of LinkedIn, another Rivers School alumni, discussed the importance of building your personal brand.